

# **CURRICULUM VITAE**

## **SECTION A**

### **Personal Information**

**NAME** EDWARD BERNARD JUDE

**ADDRESS** 23 Sandiway  
Bramhall  
Cheshire SK7 3BP

**TELEPHONE** Office: 0161 9225189  
Mobile: 07900677229

**MEDICAL SCHOOL** August 1977 - February 1982  
St. John's Medical College and Hospital  
Bangalore INDIA

**QUALIFICATIONS** **MBBS** March 1984  
**MD (General Medicine)** February 1989  
**DNB (General Medicine)** November 1991  
**MRCP (UK)** February 1994  
**MD Thesis (Bangalore University)** - Clinical and Laboratory  
Profile of patients with Hyperthyroidism 1988  
**MD (Manchester University)** Studies on the pathogenesis  
and management of the neuropathic diabetic foot in 2001

I am accredited in General (Internal) Medicine, Diabetes and Endocrinology by the JCHMT.

**GMC REGISTRATION** Full registration. Registration No: 4264518

**MEMBERSHIP OF  
LEARNED SOCIETIES** Past Chairman of European Diabetic Foot Study Group  
(Subgroup of the EASD; [www.dfsg.org](http://www.dfsg.org))  
Diabetes UK  
European Association for the Study of Diabetes (EASD)  
Medical Defence Union  
British Medical Association  
Diabetes Obesity Research Network (DORN)  
American Diabetes Association  
British Endocrine Society  
European Endocrine Society  
European Wound Management Association

**PRESENT APPOINTMENT  
2001 – to date** Consultant Physician/Diabetologist  
Tameside General Hospital, Ashton-Under-Lyne  
Honorary Professor, Manchester Metropolitan University  
Honorary Professor, University of Manchester

## **SECTION B**

### **RESEARCH CONTRIBUTIONS BI PUBLICATIONS**

#### **a) Chapters and Reviews**

1. Majumdar S, Jacob J, **Jude EB**. Obesity associated hypogonadism a growing concern in metabolic syndrome. *Metabolic Syndrome*. <https://doi.org/10.1016/B978-0-323-85732-1.00054-2>, 2023 (in press)
2. Rebelos E, Tentolouris N, **Jude EB**. The Role of Vitamin D in Health and Disease: a Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation. *Drugs* 2023 (in press)
3. Dubský M, Fejfarova V, Bem R, **Jude EB**. Pain Management in Older Adults with Chronic Wounds. *Drugs Aging*. 2022 Aug;39(8):619-629.
4. Ndip A, **Jude EB**, Boulton AJM. Inflammation in type 2 Diabetes. In *Frontiers in Inflammation: Basic biology and Clinical Aspects of Inflammation*. Eds Diegelmann RF and Chalfant CE, Bentham Publishing, 2016, Vol 1, p 164-179.
5. Ndip A, Wilkinson FL, Jude EB, Boulton AJ, Alexander MY. RANKL-OPG and RAGE modulation in vascular calcification and diabetes: novel targets for therapy. *Diabetologia*. 2014; 57:2251–2260
6. Mascarenhas JV, **Jude EB**. The charcot foot as a complication of diabetic neuropathy. *Curr Diab Rep*. 2014;14:561-567.
7. Mascarenhas J, Albayati M, Shearman C, **Jude EB**. Peripheral arterial disease. *Endocrinol Metab Clin North Am*. 2014;43:149-66
8. Cheer K, **Jude EB**. The diabetic foot. In *Vascular and Endothelial Surgery*. Eds Beard J, Gaines P, Loftus I. Saunders Elsevier, 2014, 5<sup>th</sup> Ed, p73-89.
9. Mascarenhas JV, Jude EB. Pathogenesis and medical management of diabetic Charcot neuroarthropathy. *Med Clin North Am*. 2013;97:857-72
10. Ndip A, **Jude EB**. *Diabetic Foot Disease and Wound Healing*. Eds Raj Mani, V Shukla, M Romanelli. Springer Science, London, 2012 p17-39
11. Cheer K, Jostel A, **Jude EB**. Medical Management of the Charcot Foot. In, *The Charcot Foot and Ankle: Medical management*, Ed. Robert Frykberg, Datapress, 2010, pp281-287
12. **Jude EB**, Boulton AJM. The Diabetic Foot. In *Vascular and Endovascular Surgery*, Eds Beard JD and Gaines PA, Elsevier Saunders, 2009
13. **Jude EB**, Boulton AJM. The Diabetic Foot. In *Vascular and Endovascular Surgery*, Eds Beard JD and Gaines PA, Elsevier Saunders, 2006 pp 117-138
14. **Jude EB**. Management of Diabetic Charcot arthropathy. Eds AJM Boulton, P Cavanagh, G Rayman. *The Diabetic Foot 2006*.
15. **Jude EB**, Boulton AJM. The Diabetic Foot, in *Peripheral Neuropathy*, Ed. Tesfaye S, Blackwell Science, London, 2005
16. **Jude EB**, Oyibo SO, Boulton AJM. Advances in treatment of the diabetic foot. *Millennium edition of diabetes*. 2002
17. Armstrong DG, **Jude EB**, Boulton AJM, Harkless L. Clinical assessment of the diabetic foot. Eds Veves A, LoGerfo, 2002

18. **Jude EB**, Armstrong DG, Boulton AJM. Assessment of the diabetic foot. In: Krasner DL, Rodeheaver GT, Sibbald RG (Eds). *Chronic Wound Care: a Clinical Source Book for Healthcare Professionals*, Third Ed. Wayne, PA: HMP Publications, 2001:589-597
19. **Jude EB**, Boulton AJM. Current Management of the Diabetic Foot, in *Current Perspectives in Diabetes*, Ed. Betteridge J, Blackwell Science, London, 1999, pp179-196

b) **Papers in Peer Reviewed Journals - 50 most recent papers from over 220 publications**

20. Orlando G, Brown S, **Jude E**, Bowling FL, Boulton AJM, Reeves ND. Acute Effects of Vibrating Insoles on Dynamic Balance and Gait Quality in Individuals With Diabetic Peripheral Neuropathy: A Randomized Crossover Study. *Diabetes Care*. 2024 Mar 27;dc231858. doi: 10.2337/dc23-1858. Online ahead of print.
21. Blunt C, Mathew S, Mung SM, Krishnamurthy R, **Jude EB**. Hypoglycaemia following the 2-hour 75g OGTT in pregnancy - Investigating maternal and foetal outcomes. *Diabetes Metab Syndr*. 2024 Mar 8;18(3):102977.
22. Tentolouris N, Achilla C, Anastasiou IA, Eleftheriadou I, Tentolouris A, Basoulis D, Kosta O, Lambropoulos A, Yavropoulou MP, Chatzikiyriakidou A, **Jude EB**. The Association of Vitamin D Receptor Polymorphisms with COVID-19 Severity. *Nutrients*. 2024 Mar 2;16(5):727.
23. Rebelos E, Anastasiou IA, Tentolouris A, Papanas N, **Jude E**. What is New on Diabetic Neuropathy? Insights from the 2023 ADA and EASD Conferences. *Int J Low Extrem Wounds*. 2024 Feb 28;15347346241233938. doi: 10.1177/15347346241233938.
24. RECOVERY Collaborative Group. Immunomodulatory therapy in children with paediatric inflammatory multisystem syndrome temporally associated with SARS-CoV-2 (PIMS-TS, MIS-C; RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Child Adolesc Health*. 2024 Mar;8(3):190-200.
25. THE EFFECT OF THE DIFFERENT WAVES OF COVID-19 PANDEMIC ON THE OUTCOME OF DIABETIC FOOT ULCERS. Ghanshyam Goyal, Sujoy Majumdar, Usashi Biswas Bose, Ms Rekha Shrivastava, J. J. Mukherjee, S. P. Banka, S. Kapoor, **E. Jude**. *International J Lower Extrem Wounds* 2024 (in press)
26. RIFAMPICIN IN THE TREATMENT OF REFRACTORY DIABETIC FOOT ULCER AND DIABETIC FOOT OSTEOMYELITIS- AN OBSERVATIONAL STUDY  
Ghanshyam Goyal, Sujoy Majumdar, Usashi Biswas Bose, Rekha Shrivastava, S P Banka, J K Sharma, **Edward B Jude**. *International J Lower Extrem Wounds* 2024 (in press)
27. Munshi M, Ritzel R, **Jude EB**, Terry Dex<sup>4</sup>, Melas-Melt L, Rosenstock J. Advancing type 2 diabetes therapy with iGlarLixi in older people: pooled analysis of four randomized controlled trials. *Diabetes Obesity Metab* 2024 Mar;26(3):851-859.
28. RECOVERY Collaborative Group. Empagliflozin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. *Lancet Diabetes Endocrinol*. 2023 Oct 18;S2213-8587
29. Rastogi A, Sudhayakumar A, Schaper NC, **Jude EB**. A paradigm shift for cardiovascular outcome evaluation in diabetes: Major adverse cardiovascular events (MACE) to major adverse vascular events (MAVE). *Diabetes Metab Syndr*. 2023 Oct 12;17(11):102875.
30. Dubský M, Husáková J, Sojákova D, Fejfarová V, **Jude EB**. Cell Therapy of Severe Ischemia in People with Diabetic Foot Ulcers-Do We Have Enough Evidence? *Mol Diagn Ther*. 2023 Nov;27(6):673-683.

31. Coe C, Chirputkar K, Joseph L, **Jude EB**. Pedal acrometastasis secondary to urothelial carcinoma masquerading as Charcot arthropathy in a patient with diabetes. *BMJ Case Rep*. 2023 Sep 20;16(9):e254468
32. Stedman M, Robinson A, Dunn G, Meza-Torres B, Gibson JM, Reeves ND, **Jude EB**, Feher M, Rayman G, Whyte MB, Edmonds M, Heald AH. Diabetes foot complications and standardized mortality rate in type 2 diabetes. *Diabetes Obes Metab*. 2023 Sep 18. doi: 10.1111/dom.15260
33. COVID-19 Host Genetics Initiative. A second update on mapping the human genetic architecture of COVID-19. *Nature*. 2023 Sep;621(7977):E7-E26. doi: 10.1038/s41586-023-06355-3
34. Dubsky M, Veleba J, Sojakova D, Marhefkova N, Fejfarova V, **Jude EB**. Endothelial Dysfunction in Diabetes Mellitus: New Insights. *J Mol Sci*. 2023 Jun 27;24(13):10705.
35. Coe C, Mathew SV, **Jude EB**. Euvolaemic hyponatraemia as a rare first presentation of chronic hypopituitarism. *BMJ Case Rep*. 2023 Jun 19;16(6):e254469.
36. Rebelos E, Tentolouris N, **Jude E**. The Role of Vitamin D in Health and Disease: A Narrative Review on the Mechanisms Linking Vitamin D with Disease and the Effects of Supplementation. *Drugs*. 2023 Jun;83(8):665-685.
37. Mathew S, Ellis T, **Jude EB**. Parathyroid Carcinoma Presenting as Severe Hypercalcaemia Responding to Steroids. *BMJ case reports* 2023 May 2;16(5):e252120.
38. Mung SM, Goh TL, Hughes M, **Jude EB**. Inflammatory Arthritis Associated with COVID-19 Vaccination. *Cureus*. 2023 Mar 9;15(3):e35951. doi: 10.7759/cureus.35951. eCollection 2023 Mar.
39. Rastogi A, Saini U, **Jude E**. Ankle Charcot Mimics: Tubercular Rheumatism to Complex Regional Pain Syndrome. *J Am Podiatr Med Assoc*. 2022 Nov-Dec;112(6):21-122. doi: 10.7547/21-122.
40. Marshall A, Kalteniece A, Ferdousi M, Azmi S, **Jude EB**, Adamson C, D'Onofrio L, Dhage S, Soran H, Campbell J, Lee-Kubli CA, Hamdy S, Malik RA, Calcutt NA, Marshall AG. Spinal disinhibition: evidence for a hyperpathia phenotype in painful diabetic neuropathy. *Brain Commun*. 2023 Feb 28;5(2):fcad051.
41. Fermin R Martinez-De Jesús, Robert Frykberg, and Elízabeth Zambrano-Loaiza, Edward B Jude Re-epithelialization of neuropathic diabetic foot wounds with the use of cryopreserved allografts of human epidermal keratinocyte cultures (Epifast). *J Clin Med* 2022;Dec10; 11(24)7348
42. Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT. Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Young T, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Julious SA, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, **Jude E**, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsalidis V, Johnson M, Bouhassira D, Bennett DL, Selvarajah D. *Health Technol Assess*. 2022 Oct;26(39):1-100. doi: 10.3310/RXUO6757.
43. Vlachos B, **Jude EB**, Mauricio D. Prevalence and risk factors of diabetic foot disease among the people with type 2 diabetes using real-world practice data from Catalonia during 2018. *Frontiers Endocrinology* 2022 Oct 24;13: 1024904
44. Michal Dubský, Jitka Husáková, Robert Bem, Alexandra Jirkovská, Andrea Němcová, Vladimíra Fejfarová, Karol Sutoris, Michal Kahle, **Edward B. Jude**. Comparison of the impact of autologous cell therapy and conservative standard treatment on tissue oxygen supply and course of the diabetic foot in patients with chronic limb-threatening ischemia. A randomized controlled trial. *Front Endocrinol* 2022; Aug 29;13:888809. doi: 10.3389/fendo.2022.888809.
45. RECOVERY Collaborative Group. Baricitinib in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial and updated meta-analysis. *Lancet*. 2022 Jul 30;400(10349):359-368.

46. Marshall A, Kalteniece A, Ferdousi M, Azmi S, **Jude EB**, Adamson C, D'Onofrio L, Dhage S, Soran H, Campbell J, Lee-Kubli CA, Hamdy S, Malik RA, Calcutt NA, Marshall AG. Spinal disinhibition: evidence for a hyperpathia phenotype in painful diabetic neuropathy. *Brain Commun.* 2023 Feb 28;5(2):fcad051.
47. Fermin R Martinez-De Jesús, Robert Frykberg, Elizabeth Zambrano-Loaiza, **Jude EB**. Re-epithelialization of neuropathic diabetic foot wounds with the use of cryopreserved allografts of human epidermal keratinocyte cultures (Epifast). *J Clin Med* 2022;Dec10; 11(24)7348
48. Optimal pharmacotherapy pathway in adults with diabetic peripheral neuropathic pain: the OPTION-DM RCT. Tesfaye S, Sloan G, Petrie J, White D, Bradburn M, Young T, Rajbhandari S, Sharma S, Rayman G, Gouni R, Alam U, Julious SA, Cooper C, Loban A, Sutherland K, Glover R, Waterhouse S, Turton E, Horspool M, Gandhi R, Maguire D, **Jude E**, Ahmed SH, Vas P, Hariman C, McDougall C, Devers M, Tsalidis V, Johnson M, Bouhassira D, Bennett DL, Selvarajah D. *Health Technol Assess.* 2022 Oct;26(39):1-100. doi: 10.3310/RXUO6757.
49. Vlachos B, **Jude EB**, Mauricio D. Prevalence and risk factors of diabetic foot disease among the people with type 2 diabetes using real-world practice data from Catalonia during 2018. *Frontiers Endocrinology* 2022 Oct 24;13: 1024904
50. Michal Dubský, Jitka Husáková, Robert Bem, Alexandra Jirkovská, Andrea Němcová, Vladimíra Fejfarová, Karol Sutoris, Michal Kahle, **Edward B. Jude**. Comparison of the impact of autologous cell therapy and conservative standard treatment on tissue oxygen supply and course of the diabetic foot in patients with chronic limb-threatening ischemia. A randomized controlled trial. *Front Endocrinol* 2022; Aug 29;13:888809. doi: 10.3389/fendo.2022.888809.

d) **Abstracts and Conference contributions – Selection from over 200 abstracts**

1. **Jude EB**, A. Ali, R. Emral<sup>3</sup>, N. Nanda, R. Lubwam, K. Palmer, A. Shaunik, P. Raskin, F. Gómez Peralta, C. Trescoli. Effectiveness of Premix Insulin (Premix) in Type 2 Diabetes (T2D): A Retrospective UK Cohort Study. Presented at the American Diabetes Association in Chicago, 2020
2. Todorova A, Dimova R, Chakarova N, Serdarova M, Grozeva G, Tsarkova P, Tankova T, **Jude EB**. Vitamin D status in a Bulgarian population with type 2 diabetes and diabetic foot ulcers. Presented at the American Diabetes Association in Chicago, 2020
3. Anna Stepanova, Tatiana Karonova, Anna Bystrova, Edward B. Jude. High-dose vitamin D supplementation reduces inflammation and improves microcirculation in patients with diabetic peripheral neuropathy – A Randomized Control Trial. Presented at the American Diabetes Association, San Francisco, 2019
4. **Jude EB**, Myland M, Nixon M, Gooch N, O'Leary C, Shaunik A, Lew E. Impact of treatment intensification in patients with suboptimally controlled T2D within The Health Improvement Network (THIN) UK primary care database. Accepted for Diabetes UK, London, 2018
5. Eleftheriadou I, Dimitrakopoulou N, Kafasi N, Dimitrakopoulou A, **Jude E**, Tentolouris N. Endothelial progenitor cells are increased in patients with type 2 diabetes and peripheral neuropathy. Presented at EASD, Lisbon 2017
6. Maiya A, Prabhath K, Shubha G, Kumar S, Kumar S, Hande H, Ramachandra L, Animesh H, **Jude E**. Prevalence of Foot Complications in Type 2 Diabetes Mellitus in Udupi District Karnataka, India. International Diabetes Federation, Abu Dhabi, 2017
7. Eleftheriadou I, Mourouzis I, **Jude E**, Fontaine J, Catrina E, Tentolouris A, Papadimitriou C, Maria K, Tentolouris N. Bone immunohistochemistry and levels of RANKL, osteoprotegerin and inflammatory cytokines in acute charcot foot. DFSG, Porto, 2017
8. N. Tentolouris, N. Papanas, G. Panagoulas, D. Tessic, S. Z. Kamenov, C. Manes, Bousboulas, E. Jude. The association between Neuropad testing with foot ulceration in diabetes. EASD, 2014

9. Azmi S, **Jude EB**. Hypoglycaemia as a risk factor for mortality in patients admitted to the acute medical admission unit. *Diabetes UK*, London, March 2011.
10. Ndip A, Alexander Y, Williams A, **Jude EB**, Boulton A. RANKL/OPG signalling pathway mediates medial arterial calcification in diabetic Charcot Neuroarthropathy. Presented at EASD, Sweden, 2010.
11. Garrow A, **Jude EB**. Role of acupuncture in painful diabetic neuropathy. Presented at Diabetic Foot Study Group meeting, Sweden, 2010.
12. Forth R, Vere J, Tentolouris N, **Jude EB**. The performance of the visual test Neuropad for the diagnosis of neuropathy in diabetes: a meta-analysis. Presented at DFSG, Sweden, 2010.
13. **Jude EB**, Ndip A, Boulton AJM. Serum Levels of the Receptor Activator of Nuclear factor Kappa-B ligand (RANK-L) and its Decoy Receptor, Osteoprotegerin (OPG) are high in Acute Phase Charcot Neuroarthropathy and Decreased in the Quiescent Phase. Presented at the American Diabetes Association meeting in New Orleans, June 2009.
14. Cheer K, Vere J, **Jude EB**. A Study of Inpatient Care of Patients with Diabetic Foot Ulcers in a District General Hospital. Presented at Diabetic Foot Study Group meeting, Slovenia, 2009
15. Forth R, Cheer K, Vere J, **Jude EB**. Predictive Factors and outcomes of Diabetic Foot Ulcers Presented at Diabetic Foot Study Group meeting, Slovenia, 2009
16. **Jude EB**, N Apostolopoulos, R Berry, AJ Watson, L Mohiyiddeen. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome (PCOS). Presented at the American Endocrine Society meeting in Toronto, 2007
17. Paraiso H, **Jude EB**. A modified Apache scoring system in acutely ill diabetic patients. *Diabetic Medicine* 2005; (suppl 1) A 69
18. **Jude EB**. Aquacel Ag in the management of non-infected neuropathic diabetic foot ulcers. *Diabetic Medicine* 2005; (suppl 1): P165
19. George J, Gibbons J, Cuong D, **Jude EB**. Infections in diabetic foot ulcers: associated factors and outcomes. *Diabetic Medicine* 2004
20. **Jude EB**, Tentolouris N, Al-Sabbagh S, Dewan S, et al. No change in amputation rates in three hospitals in the North-West of England. *Diabetic Medicine* 2003; 20 (suppl 2): P222
21. Kamineni S, Marimon M, Hood W, **Jude EB**. Hyperglycaemia as a marker of higher mortality in patients attending accident and emergency department in a district general hospital. *Diabetic Medicine* 2003; 20 (suppl 2):P241
22. **Jude EB**, Selby PL, Mawer EB, Burgess J, Boulton AJM. Inflammatory and bone turnover markers in Charcot arthropathy and osteomyelitis of the feet in diabetic patients. *Diabetologia* 2002; 45 (Suppl 1):1056
23. Dang C, Prasad M, Boulton AJM, **Jude EB**. Methicillin-resistant staphylococcus aureus in the diabetic foot clinic: the problem is getting worse. *Diabetologia* 2002; 45 (Suppl 1):6
24. Tentolouris N, Sabbagh A, Boulton AJM, **Jude EB**. Mortality in diabetic and non-diabetic patients after amputations. *Diabetologia* 2002; 45 (Suppl 1):1047
25. Abouesha F, Van Schie C, Carrington A, **Jude EB**, Boulton AJM. Neuropathic and vascular profiles in diabetic patients with Charcot neuroarthropathy. *Diabetologia* 2002; 45 (Suppl 1):1054
26. Dewan S, **Jude EB**, Anderson SG et al. Factors associated with increased mortality in diabetic patients undergoing amputations. *Diabetologia* 2001; 44 (Suppl 1): A1078
27. Oyibo SO, Prasad YDM, Jackson NJ, **Jude EB**, Boulton AJM. The relationship between blood glucose excursions and painful diabetic peripheral neuropathy. *Diabetologia* 2001; 44 (Suppl 1): A1149
28. **Jude EB**, Rogers AA, Oyibo SG et al. Matrix metalloproteinase and tissue inhibitors of MMPs expression in venous and diabetic foot ulcers. *Diabetologia* 2001; 44 (Suppl 1):A3
29. **Jude EB**, Page S, Mawer EB, Burgess J, Edmonds ME, Foster A, Dohono M, Selby PL. Pamidronate in Diabetic Charcot Neuroarthropathy: A Randomised Placebo Controlled Trial. *Diabetes* 2000; A65

e) **H-index**

My H- index is 63 (as calculated by the University of Manchester).

## **B3 ORGANISATION AND PROMOTION OF RESEARCH**

### **(1) RESEARCH GRANTS SECURED**

Since commencing my post as Consultant at Tameside General Hospital I have been successful in raising the following funds for research:

#### **Chief Investigator:**

Convatec – 2001-2002 – Hyalofill in diabetic foot ulcers

BMS – 2002- 2003 - Aquacel Ag in diabetic foot ulcers

Department of health (NIHRfPB) – 2008 - Painful neuropathy and acupuncture

MIRO (Germany) – 2009 - Neuropad in the diagnosis of diabetic neuropathy

Bayer – 2012 – Effect of testosterone on endothelial function and microcirculation in type 2 diabetic patients with hypogonadism.

ELIXA study – Lixisenatide treatment in type 2 diabetes with acute coronary syndrome (Ongoing). I am the CI for the UK co-ordinating over 25 centres, as part of a multinational study.

TrusTec – 2013 - A study to evaluate the performance of the VibraTip® product by different community medical practitioners compared to an expert validation by a Diabetologists – Lead applicant – 1 year

#### **Principal Investigator:**

Aventis – 2001-2002 – Glargine in type 2 diabetes

J&J - 2001-2002 – Promogran in diabetic foot ulcers

Grants from NIH (USA) – 2003-2009 - Stress and wound healing in diabetes

Convatec – 2003 – Hyalofill and Aquacel Ag in diabetic foot ulcers with sinuses

Diabetes UK – 2004-2006 - The establishment of a collaborative network for the study of the Charcot foot

Diabetes UK – 2003-2007 - Alendronate in diabetic Charcot arthropathy

Merck Link Grant 2004-2007

MRC/Link 2002-2004. The genetic differences between chronic diabetic wounds compared to acute wounds

European Commission – 2002-2005 - Multi-centre observational study describing usual care, outcome and health care organisation for diabetic patients with an ulcerated foot in 13 European Centres – 500,000 euros

Department of Health (HTA) – 2010 - **CO**ncordance in **DI**abetic **F**oot **I**nfection (**CODIFI**) – £499,999

IHUT study – 2011- Ease of Use of New BGM with In-Built Insulin Calculator at Home Study

HTA 2016 – Optimal Pathway for Treating Neuropathic Pain in Diabetes Mellitus - £2.97m

HTA 2016 – Multiple Interventions for Diabetic Foot Ulcer Treatment - £1.8m

Educational grant 2021 – Sanofi - £50,000

Educational grant 2021 – Novo Nordisk - £35,000

### **(3) RESEARCH ACTIVITIES**

Despite Tameside General Hospital being a DGH I have actively promoted research here by appointing research nurses and research fellows. This has been demonstrated by my collaborations, publications and securing grants for research. I am also active member on the research committee.

Since joining Tameside Hospital I have been active in research. I have received grants from various charitable organisations and also from pharmaceutical companies. I have also received funding from Diabetes UK, the European Commission, Department of Health (NIHR), Health Technology Assessment, Medical Research Council and National Institute of Health (USA).

My research interest is in the diabetic foot and neuropathy. I have also been involved in trials on endothelial function in patients with diabetes and polycystic ovarian syndrome. My other interests are in wound healing and with Professor Boulton we were successful in securing a grant from the NIH (US) looking at depression and its role in wound healing. With Professor Boulton and Professor Ferguson we studied the genetics of wound healing and were granted funding from the MRC.

I was also awarded a grant from Diabetes UK to start a register on Charcot neuroarthropathy. This was in collaboration with Dr Jeffcoate, Nottingham and Dr Jones, Blackburn. This is a web based register and diabetologists and podiatrists from the UK were invited to be part of it and to enter patients with acute Charcot foot on the register from which we hope to understand better the natural history of this condition. This has been presented at international conferences.

With Professor Boulton and Professor Ferguson we looked at the genetics of wound healing in chronic diabetic and venous ulcers. This was funded by the Medical Research Council.

In Tameside General Hospital I collaborated with Dr Watson, Consultant Gynaecologist, Department of Obstetrics & Gynaecology and we assessed endothelial dysfunction in patients with polycystic ovarian syndrome. In this study we investigated the effect of rosiglitazone on endothelial function in patients with PCOS. This has been submitted to Journal of Gynaecology.

Our centre was one of 13 European centres to conduct a study on the natural history and epidemiology of diabetic foot ulcers. This study was funded by the European Commission. In this study of 1229 diabetic foot ulcer patients we collected data at 1 and 2 years after the development of the foot ulcer. We have twelve publications from this study in peer reviewed journals.

I was the Chief Investigator for the UK for the ELIXA study that looked at the benefit of Lixisenatide in type 2 diabetes patients involving over 6000 patients world wide. We were the highest recruiters in the UK for this study.

I have worked closely with Universities in the UK and am co-investigator in a number of grants. More recently we have received two grants from the Department of health (HTA) on diabetic neuropathy and diabetic foot ulcers management

#### **4) ORGANISATION, PROMOTION AND MANAGEMENT OF RESEARCH**

I have actively promoted research in Tameside Hospital. I facilitated the setting up of the R&D and sit on the committee and have helped enhance research in the trust. I have encouraged consultants and juniors as well as GPs to partake in research. To promote and disseminate the research in Tameside I proposed that we have a R&D day and this was held for 3 consecutive years. We had invited speakers on this day and included Professor Tony Heagerty (University of Manchester) and Professor Alex Mollasiotis (UoM)

Set up the first UK Charcot Register with Nottingham/London, to assess care provided to diabetic patients with Charcot arthropathy. Data presented at the American Diabetes Association conference in 2007. We have set up a Charcot committee under the auspices of Diabetes U K.

Have actively collaborated with Universities in the UK and abroad. I have secured funding from the HTA in collaboration with UK universities.

I appointed and co-supervised a research fellow who completed her MD in 2017.

I was appointed as a member of the European Wound Management Association Council and have actively promoted research on wounds through this council by advising the council on diabetic foot wounds and wrote up guidelines for management of diabetic foot uclers.



I was invited by the President of the International Diabetes Federation to write the guidelines on the Diabetic Foot. I was co-secretary of the guidelines writing committee with Dr Langton from Canada. I presented the guidelines at the IDF meeting in Abu Dhabi in December 2017.